• 1
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN, version 2.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10. Lyon, France: International Agency for Research on Cancer; 2010. Accessed on February 21, 2013.
  • 2
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:12451255.
  • 3
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:1130.
  • 4
    Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:14851491.
  • 5
    Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010;10(4 pt 2):10031019.
  • 6
    Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:13421351.
  • 7
    Surveillance, Epidemiology, and End Results (SEER) Program.SEER*Stat Database: Incidence-SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov. 2011 Sub (1973–2009)-Linked To County Attributes-Total US, 1969–2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012, based on the November 2011 submission.
  • 8
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457481.
  • 9
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163170.
  • 10
    Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187220.
  • 11
    National Cancer Institute.Surveillance Research Program, National Cancer Institute SEER*Stat software. Version 8.0.1. Access date.
  • 12
    StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
  • 13
    Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38:703712.
  • 14
    Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in Surveillance, Epidemiology, and End Results registries, 1992–2008. Hepatology. 2012;55:476482.
  • 15
    Cance WG, Stewart AK, Menck HR. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer. 2000;88:912920.
  • 16
    Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the Medicare population. Cancer. 2011;117:10191026.
  • 17
    Zak Y, Rhoads KF, Visser BC. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg. 2011;146:778784.
  • 18
    Wang J, Wang FW. Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. Int J Surg Oncol. 2010;2010:381795.
  • 19
    O'Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol. 2004;11:962969.
  • 20
    Yeh CN, Lee WC, Jeng LB, Chen MF. Hepatic resection for hepatocellular carcinoma in elderly patients. Hepatogastroenterology. 2004;51:219223.
  • 21
    Tsukioka G, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol. 2006;12:4853.
  • 22
    Pignata S, Gallo C, Daniele B, et al;CLIP Investigators. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol. 2006;59:243249.
  • 23
    Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA. 2008;300:23712378.
  • 24
    Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores–a systematic bias. Am J Transplant. 2007;7:685692.
  • 25
    Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant. 2010;10:26582664.
  • 26
    Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006;98:19341939.
  • 27
    Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6:182187.
  • 28
    Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799805.
  • 29
    Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145:11581163.
  • 30
    Yip B, Wantuck JM, Kim LH, Wong RJ, Ahmed A, Garcia G, Nguyen MH. Clinical Presentation and survival of Asian and Non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci. 2014;59:192200.